282 related articles for article (PubMed ID: 23702094)
1. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
[TBL] [Abstract][Full Text] [Related]
4. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
[TBL] [Abstract][Full Text] [Related]
5. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.
Manousopoulou A; Scorletti E; Smith DE; Teng J; Fotopoulos M; Roumeliotis TI; Clough GF; Calder PC; Byrne CD; Garbis SD
Clin Nutr; 2019 Aug; 38(4):1952-1955. PubMed ID: 30172659
[TBL] [Abstract][Full Text] [Related]
6. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
[TBL] [Abstract][Full Text] [Related]
8. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
[TBL] [Abstract][Full Text] [Related]
9. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN).
Tobin D; Brevik-Andersen M; Qin Y; Innes JK; Calder PC
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30127297
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
12. Effect of prenatal EPA and DHA on maternal and cord blood insulin sensitivity: a secondary analysis of the mothers, omega 3, and mental health study.
England JA; Jain J; Holbrook BD; Schrader R; Qualls C; Mozurkewich E
BMC Pregnancy Childbirth; 2019 Nov; 19(1):452. PubMed ID: 31783739
[TBL] [Abstract][Full Text] [Related]
13. Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults.
Gold DR; Litonjua AA; Carey VJ; Manson JE; Buring JE; Lee IM; Gordon D; Walter J; Friedenberg G; Hankinson JL; Copeland T; Luttmann-Gibson H
Contemp Clin Trials; 2016 Mar; 47():185-95. PubMed ID: 26784651
[TBL] [Abstract][Full Text] [Related]
14. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
15. The mothers, Omega-3 and mental health study.
Mozurkewich E; Chilimigras J; Klemens C; Keeton K; Allbaugh L; Hamilton S; Berman D; Vazquez D; Marcus S; Djuric Z; Vahratian A
BMC Pregnancy Childbirth; 2011 Jun; 11():46. PubMed ID: 21696635
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
17. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
18. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
Age-Related Eye Disease Study 2 Research Group
JAMA; 2013 May; 309(19):2005-15. PubMed ID: 23644932
[TBL] [Abstract][Full Text] [Related]
19. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.
Dasarathy S; Dasarathy J; Khiyami A; Yerian L; Hawkins C; Sargent R; McCullough AJ
J Clin Gastroenterol; 2015 Feb; 49(2):137-44. PubMed ID: 24583757
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL).
Bassuk SS; Manson JE; Lee IM; Cook NR; Christen WG; Bubes VY; Gordon DS; Copeland T; Friedenberg G; D'Agostino DM; Ridge CY; MacFadyen JG; Kalan K; Buring JE
Contemp Clin Trials; 2016 Mar; 47():235-43. PubMed ID: 26767629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
